Acadia Pharmaceuticals Inc’s filing revealed that its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported $14420.0 on Jun 10 ’24. In the deal valued at $14.79 per share,975 shares were sold. As a result of this transaction, Schneyer Mark C. now holds 34,564 shares worth roughly $0.55 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, DAVIS STEPHEN sold 11,427 shares, generating $193,573 in total proceeds. Upon selling the shares at $16.94, the CEO now owns 155,231 shares.
Before that, Schneyer Mark C. sold 3,503 shares. Acadia Pharmaceuticals Inc shares valued at $59,341 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $16.94 per share. As a result of the transaction, Schneyer Mark C. now holds 32,053 shares, worth roughly $0.51 million.
BMO Capital Markets initiated its Acadia Pharmaceuticals Inc [ACAD] rating to an Outperform in a research note published on June 27, 2024; the price target was $31. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in mid March has reiterated a ‘”a Buy”‘ rating for it. Mizuho also remained covering ACAD and has decreased its forecast on March 12, 2024 with a “Neutral” recommendation from previously “Buy” rating. Robert W. Baird started covering the stock on January 30, 2024. It rated ACAD as “an Outperform”.
Price Performance Review of ACAD
On Monday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -1.29% to $16.04. Over the last five days, the stock has gained 1.01%. Acadia Pharmaceuticals Inc shares have fallen nearly -48.77% since the year began. Nevertheless, the stocks have fallen -33.17% over the past one year. While a 52-week high of $33.99 was reached on 01/02/24, a 52-week low of $14.55 was recorded on 06/10/24. SMA at 50 days reached $15.71, while 200 days put it at $21.67. A total of 1.12 million shares were traded, compared to the trading of 1.81 million shares in the previous session.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 15.82, which if violated will result in even more drops to 15.59. On the upside, there is a resistance level at 16.34. A further resistance level may holdings at 16.63. The Relative Strength Index (RSI) on the 14-day chart is 56.61, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.81, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 25.45%. Stochastics%K at 84.16% indicates the stock is a selling.
